Galecto
GLTO
NASDAQ
IPO2020
about GLTO
Galecto is a biopharmaceutical company focused on developing innovative therapies for rare diseases, including its lead product Mogamulizumab for certain blood cancers and other investigational treatments.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $21.44 | $25.88 | $15.06 | $6.56M | 43.78M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$2.36 | n/a | 660.99 | -7514.29% | -7380.95% | 0% |